[1]
|
Kuroda, J., Kimura, S., Andreeff, M., et al (2007) ABT-737 is a useful component of combinatory chemo-therapies for chronic myeloid leukaemias with diverse drug-resistance mechanisms. British Journal of Haema-tology, 140, 181-190.
|
[2]
|
Deininger, M., Buchdunger, E., Druker, B.J., et al (2005) The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood, 105, 2640-53.
|
[3]
|
Dulucq, S., Bouchet, S., Turcq, B., et al (2008) Mul-tidrug resistance gene (MDR1) polymorphisms are asso-ciated with major molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood, 112, 2024-2027.
|
[4]
|
Kikuchi, S., Nagai, T., Kunitam, M., et al (2007) Active FKHRL1 overcomes imatinib resistance in chronic mye-logenous leukemia-derived cell lines via the production of tumor necrosis factor-related apoptosis-inducing ligand. Cancer Sci, 98(12),1949-58.
|
[5]
|
Heaney, N.B., Holyoake, T.L. (2007) Therapeutic targets in chronic myeloid leukaemia. Hematol. Oncol, 25, 66-75.
|
[6]
|
Baran, Y., Salas, A., Senkal, C., et al (2007) Alterations of ceramide/sphingosine 1-phosphate rheostat involved in the regulation of resistance to imatinib-induced apop-tosis in K562 human chronic myeloid leukemia cells. The J of Biol Chem, 282(15), 10922-10934.
|
[7]
|
Baran, Y., Ural, A.U., Gunduz, U. (2007) Mechanisms of cellular resistance to imatinib in human chronic myeloid leukemia cells. Hematology, 12, 497-503.
|
[8]
|
Fausel, C. (2007) Targeted chronic myeloid leukemia therapy: Seeking a cure. J. of Managed Care Pharmacy, 13(8), 8-12.
|
[9]
|
Talpaz, M., Shah, N.P., Kantarjian, H., et al (2006) Dasatinib in imatinib-resistant Philadelphia chromo-some–positive leukemias. N Engl J Med, 354, 2531-41.
|
[10]
|
Kuroda, J., Kimura, S., Strasser, A., et al (2007) Apop-tosis-based dual molecular targeting by INNO-406, a second-generation BCR/ABL inhibitor, and ABT-737, an inhibitor of antiapoptotic Bcl-2 proteins, against BCR/ABL-positive leukemia. Cell Death and Differen-tiation, 14, 1667-1677.
|
[11]
|
Quintas-Cardama, A., Cortes, J. (2008) Molecular biol-ogy of bcr-abl1-positive chronic myeloid leukemia. Blood, Doi:10.1182/blood-2008-03-144790.
|
[12]
|
Kwee, J.K., Luque, D.G., dos Santos Ferreira, A.C., et al (2008) Modulation of reactive oxygen species by anti-oxidants in chronic myeloid leukemia cells enhances imatinib sensitivity through survivin downregulation. Anti-Cancer Drugs, 19, 975–981.
|
[13]
|
Wiberg, K., Carlson, K., Aleskog, A., et al (2008) In vitro activity of bortezomib in cultures of patient tumour cells—potential utility in haematological malignancies. Med Oncol, Doi:10.1007/s12032-008-9107-6.
|
[14]
|
Fennell, D.A., Chacko, A., Mutti, L. (2008) BCL-2 fam-ily regulation by the 20S proteasome inhibitor borte-zomib. Oncogene, 27, 1189–1197.
|
[15]
|
Faderl, S., Rai, K., Gribben, J., et al (2006) Phase II study of single-agent bortezomib for the treatment of pa-tients with fludarabine-refractory B-cell chronic lym-phocytic leuk cancer. 107(5), 916-24.
|
[16]
|
Galimberti, S., Canestraro, M., Pacini, S., et al (2008) PS-341 (bortezomib) inhibits proliferation and induces apoptosis of megakaryoblastic MO7-e cells. Leuk Res, 32(1), 103-12.
|
[17]
|
Combaret, V., Boyault, S., Iacono, I., et al (2008) Effect of bortezomib on human neuroblastoma: analysis of mo-lecular mechanisms involved in cytotoxicity. Mol Cancer, Doi:10.1186/1476-4598-7-50.
|
[18]
|
McCloskey, S.M., McMullin, M.F., Walker, B., et al (2008) The therapeutic potential of the proteasome in leukaemia. Hematol Oncol, 26, 73-81.
|
[19]
|
Barr, P., Fisher, R., Friedberg J. (2007) The role of bor-tezomib in the treatment of lymphoma. Can Invest, 25, 766-775.
|
[20]
|
Armand, J.-P., Burnett, A.K., Drach, J., et al (2007) The emerging role of targeted therapy for hematologic ma-lignancies: Update on bortezomib and tipifarnib. The Oncologist, 12, 281-290.
|
[21]
|
Ludwig, H., Khayat, D., Giaccone, G., et al (2005) Pro-teasome inhibition and its clinical prospects in the treat-ment of hematologic and solid malignancies. Cancer, 104(9), 1794-1807.
|
[22]
|
Gore, S.D., Hermes-DeSantis, E.R. (2008) Future direc-tions in myelodysplastic syndrome: Newer agents and the role of combination approaches. Cancer Control, 15(4), 40-9.
|
[23]
|
Hind, D., Tappenden, P., Tumur, I., et al (2008) The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: Systematic review and economic evaluation. Health Technol Assess, 12(15), 1-182.
|
[24]
|
Shimizu, H., Tanaka, K., Ikeda, S., et al (2008) Util-ity-based evaluation of the quality of life of patient's with gastric cancer who receive chemotherapy--comparison of patients' quality of life between oral TS-1 and conven-tional injectable combination therapy. Yakugaku Zassh,i 28(5), 783-93.
|
[25]
|
Shen, L., Au, W.-Y., Guo, T., et al (2007) Proteasome inhibitor bortezomib-induced apoptosis in natural killer (NK)–cell leukemia and lymphoma: an in vitro and in vivo preclinical evaluation. Blood, 110, 469-470.
|
[26]
|
Yong, A.S.M., Keyvanfar, K., Hensel, N., et al. (2008) Primitive quiescent CD34+ cells in chronic myeloid leu-kemia are targeted by in vitro expanded natural killer cells, which are functionally enhanced by bortezomib. Blood, Doi:10.1182/blood-2008-05-158253.
|
[27]
|
Yu, C., Friday, B.B., Lai, J.-P., et al (2006) Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways. Mol Cancer Ther, 5(9),2378–87.
|
[28]
|
Yu, C., Rahmani, M., Conrad, D., et al (2003) The pro-teasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl cells sensitive and resistant to STI571. Blood, 102, 3765-3774.
|
[29]
|
Fruehauf, S., Topaly, J., Buss, E.C., et al (2007) Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis. Cancer, 109(8), 1543-9.
|